NDA 020258 · Harrow Eye
Iopidine
Apraclonidine Hydrochloride · Ophthalmic
Priority reviewLast checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jul 30, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 2 recruiting
FAERS reports
111
87 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 2, 2024.
INDICATIONS AND USAGE Apraclonidine ophthalmic solution 0.5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional IOP reduction. Patients on maximally tolerated medical therapy, who are treated with apraclonidine ophthalmic solution 0.5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the IOP rises significantly. The addition of apraclonidine ophthalmic solution 0.5% to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine ophthalmic solution 0.5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP lowering efficacy of apraclonidine ophthalmic solution 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 1993 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- IOPIDINE · APRACLONIDINE HYDROCHLORIDE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Apraclonidine" as an intervention, any sponsor and status, largest first.
- An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06538662 · 284 participants · Start Oct 7, 2024 · Primary completion Jan 27, 2025
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness; Eye Irritation
Sites: Newport Beach, California; Colorado Springs, Colorado; Louisville, Kentucky · 8 sites in all
- Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07531043 · 230 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 2027
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Los Angeles, California; Newport Beach, California; Pittsburg, Kansas · 9 sites in all
- An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsPivotal-lookingRecruiting
Alcon ResearchIndustry
NCT07578363 · 178 participants (planned) · Start Sep 27, 2026 · Primary completion Nov 2026
Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free; Vehicle · For: Ocular Hyperemia
Sites: Northbrook, Illinois; Garner, North Carolina; Shelby, North Carolina · 5 sites in all
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular RednessPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06444529 · 159 participants · Start Aug 21, 2024 · Primary completion Nov 14, 2024
Drug: Apraclonidine Hydrochloride Ophthalmic Solution; Vehicle · For: Ocular Redness
Sites: Glendale, California; Garner, North Carolina; Cranberry Township, Pennsylvania · 5 sites in all
- Iopidine to Decrease Intraocular Pressure Rise After InjectionsPivotal-lookingNot yet recruiting
Retina Consultants of DelmarvaAcademic, hospital or other
NCT07891910 · 120 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2026
Drug: Apraclonidine 1.0% ophthalmic solution · For: Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion and 1 more
Sites: Easton, Maryland
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser TrabeculoplastyStatus unknown
Walter Reed Army Medical CenterFederal agency
NCT00567411 · 43 participants (planned) · Start Aug 2006
Drug: brimonidine 0.1%; Apraclonidine 0.5% · For: Glaucoma; Ocular Hypertension
Sites: Washington D.C., District of Columbia
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia GravisCompleted
American University of Beirut Medical CenterAcademic, hospital or other
NCT05045248 · 10 participants · Start Jun 1, 2020 · Primary completion Apr 15, 2021
Drug: Apraclonidine Hcl 0.5% Oph Soln · For: Myasthenia Gravis; Ocular Myasthenia Gravis
Sites: Beirut, Lebanon
University of Alabama at BirminghamAcademic, hospital or other
NCT05167760 · 0 participants · Start Dec 2025 · Primary completion Nov 2027
Drug: Apraclonidine · For: Synkinesis; Facial Nerve Palsy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective21
- off label use7
- somnolence7
- eyelid ptosis6
- vision blurred6
- constipation5
- dry mouth5
- dyspnoea5
- eye pain5
- sinus bradycardia5
- tenderness5
- urinary retention5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 2 |
| 2011 | 1 |
| 2014 | 8 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 13 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 8 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Iopidine (Apraclonidine HCl)
2024 spending
$37K
Beneficiaries
31
48 claims
Per beneficiary
$1,205
$26.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $37,350 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Optogenetic Therapy for Restoring Aspects of Visual Function.
Sahel JA, Futterknecht S, Audo I, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Multicenter Study
- Apraclonidine and LASIK.
Aslanides IM, Tsiklis NS, Pallikaris IG, et al. · Ophthalmology 2005 · Comment, Letter
- Apraclonidine and my pupil.
Cambron M, Maertens H, Crevits L · Clin Auton Res 2011 · Clinical Trial
- Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.
Zhang L, Weizer JS, Musch DC · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine Gel, and Miostat.
Fry LL · J Cataract Refract Surg 1992 · Clinical Trial, Comparative Study
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.